May 20, 2022
(Reuters) – Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.
Your email address will not be published.
Save my name, email, and website in this browser for the next time I comment.